Effects of rosuvastatin and/or β-carotene on non-alcoholic fatty liver in rats
- PMID: 26600855
- PMCID: PMC4623617
Effects of rosuvastatin and/or β-carotene on non-alcoholic fatty liver in rats
Abstract
The prevalence of non-alcoholic fatty liver disease (NAFLD) has markedly increased, especially in patients exhibit one or more features of the metabolic syndrome. This study investigates the effect of rosuvastatin (RSV) and/or β-carotene (βC) in NAFLD-induced rats. Rats were classified into nine groups; normal (I), NAFLD-induced with high-fat diet (HFD; II), NAFLD switched to regular diet (RD; III), NAFLD-HFD or NAFLD-RD treated with RSV (IV, V), βC (VI, VII) or both RSV+βC (VIII, IX), respectively. After four weeks, rats were sacrificed to obtain serum samples and liver tissues. Liver histology, lipid profile, liver oxidative stress markers, and adipocytokines were measured. Liver sections of rats with NAFLD-HFD revealed steatosis, lose of hepatic architecture, inflammation and hepatocyte vacuolation with high percentage of cell fibrosis. Serum levels of ALT, AST, ALP, gamma glutamyl transferase (GGT) and lipid profile (triglycerides, cholesterol, LDL and VLDL) were significantly increased (P<0.05) compared with normal. Also, hepatic malondialdehyde level and serum leptin, tumor necrosis factor-alpha (TNF-α) and transforming growth factor-β1 (TGF-β1) were increased. Meanwhile, superoxide dismutase (SOD) activity, GSH content in liver, serum HDL and adiponectin were decreased (P<0.05) vs normal. These changes were observed to a lesser extent in NAFLD-RD group. Administration of RSV or/and βC almost improved all previously mentioned parameters. Moreover, hepatic steatosis was decreased and inflammation was markedly ameliorated with reduction of TNF-α and TGF-β. These results were more pronounced in the groups VIII and IX vs each drug alone. In conclusion RSV and βC could be beneficial for the treatment and prevention of NAFLD. Combined RSV with βC is more effective than RSV alone.
Keywords: NAFLD; Oxidative stress; Rosuvastatin; TGF-β1; TNF-α; β-carotene.
Figures



Similar articles
-
Co-administration of metformin and N-acetylcysteine with dietary control improves the biochemical and histological manifestations in rats with non-alcoholic fatty liver.Res Pharm Sci. 2016 Oct;11(5):374-382. doi: 10.4103/1735-5362.192487. Res Pharm Sci. 2016. PMID: 27920819 Free PMC article.
-
Pharmacological and antioxidant actions of garlic and.or onion in non-alcoholic fatty liver disease (NAFLD) in rats.J Egypt Soc Parasitol. 2014 Aug;44(2):295-308. doi: 10.12816/0006468. J Egypt Soc Parasitol. 2014. PMID: 25597144
-
[Effects of glucagon-like peptide-1 on liver oxidative stress, TNF-α and TGF-β1 in rats with non-alcoholic fatty liver disease].Nan Fang Yi Ke Da Xue Xue Bao. 2013 Nov;33(11):1661-4. Nan Fang Yi Ke Da Xue Xue Bao. 2013. PMID: 24273273 Chinese.
-
The protective effects of the β3 adrenergic receptor agonist BRL37344 against liver steatosis and inflammation in a rat model of high-fat diet-induced nonalcoholic fatty liver disease (NAFLD).Mol Med. 2020 Jun 5;26(1):54. doi: 10.1186/s10020-020-00164-4. Mol Med. 2020. PMID: 32503411 Free PMC article.
-
Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats.J Zhejiang Univ Sci B. 2006 Aug;7(8):627-33. doi: 10.1631/jzus.2006.B0627. J Zhejiang Univ Sci B. 2006. PMID: 16845716 Free PMC article.
Cited by
-
Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study).BMC Med. 2022 Mar 21;20(1):93. doi: 10.1186/s12916-022-02288-2. BMC Med. 2022. PMID: 35307033 Free PMC article. Clinical Trial.
-
Atorvastatin Modulates Bile Acid Homeostasis in Mice with Diet-Induced Nonalcoholic Steatohepatitis.Int J Mol Sci. 2021 Jun 16;22(12):6468. doi: 10.3390/ijms22126468. Int J Mol Sci. 2021. PMID: 34208774 Free PMC article.
-
An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease.Biomed Res Int. 2020 Jul 18;2020:4020249. doi: 10.1155/2020/4020249. eCollection 2020. Biomed Res Int. 2020. PMID: 32733940 Free PMC article. Review.
-
Micronutrients in Nonalcoholic Fatty Liver Disease Pathogenesis.Cell Mol Gastroenterol Hepatol. 2018 Aug 23;6(4):451-462. doi: 10.1016/j.jcmgh.2018.07.004. eCollection 2018. Cell Mol Gastroenterol Hepatol. 2018. PMID: 30294653 Free PMC article. Review.
-
Attenuation of Age-Related Hepatic Steatosis by Dunaliella salina Microalgae in Senescence Rats through the Regulation of Redox Status, Inflammatory Indices, and Apoptotic Biomarkers.Adv Pharmacol Pharm Sci. 2020 May 1;2020:3797218. doi: 10.1155/2020/3797218. eCollection 2020. Adv Pharmacol Pharm Sci. 2020. PMID: 32420546 Free PMC article.
References
-
- Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi KN, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, American College of Gastroenterology and the American Gastroenterological Association. Am J Gastroenterol. 2012;142:1592–1609. - PubMed
-
- Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28:155–161. - PubMed
-
- Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and non-alcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–131. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous